Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.25
+0.8%
$1.22
$0.86
$3.78
$273.41M0.313.28 million shs3.70 million shs
InterCure Ltd. stock logo
INCR
InterCure
$1.52
+1.3%
$1.52
$1.17
$2.62
$68.36M1.1825,899 shs22,951 shs
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$24.61
+2.6%
$0.00
$8.13
$34.31
$230.35M0.234,852 shs28,374 shs
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$5.69
-3.1%
$7.38
$3.50
$14.30
$268.40MN/A351,696 shs19,371 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
+0.81%-1.59%-4.62%-14.48%-63.74%
InterCure Ltd. stock logo
INCR
InterCure
0.00%-7.41%-0.07%+9.09%-37.76%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
+5.45%+5.78%-4.35%+2,397,999,900.00%+2,397,999,900.00%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
+8.50%-12.39%-22.15%-41.65%+586,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3.6711 of 5 stars
4.51.00.00.03.63.30.6
InterCure Ltd. stock logo
INCR
InterCure
0.5776 of 5 stars
0.03.00.00.02.80.00.6
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.90
Moderate Buy$8.44575.56% Upside
InterCure Ltd. stock logo
INCR
InterCure
0.00
N/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.00
Buy$64.25161.07% Upside
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INCR, ALLO, TVRD, and ZYBT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$62.00
7/11/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$52.00
6/12/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$78.00
5/21/2025
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$65.00
5/15/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $4.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.00
5/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$20K13,670.63N/AN/A$2.01 per share0.62
InterCure Ltd. stock logo
INCR
InterCure
$64.55MN/AN/AN/A$2.36 per shareN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
$7.14M32.26N/AN/A($3.02) per share-8.15
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
$25.53M10.51$0.11 per share52.50N/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)
InterCure Ltd. stock logo
INCR
InterCure
-$18.32MN/A0.00N/AN/AN/AN/A8/28/2025 (Estimated)
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
-$70.87MN/A0.00N/A-595.39%-710.04%-79.00%N/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/A0.00N/AN/AN/AN/AN/A

Latest INCR, ALLO, TVRD, and ZYBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025N/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.28-$0.28N/A-$0.28$0.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/A
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/AN/AN/AN/AN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.71
9.71
InterCure Ltd. stock logo
INCR
InterCure
0.34
1.73
1.18
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
N/A
32.48
31.73
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
InterCure Ltd. stock logo
INCR
InterCure
8.34%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
44.66%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A

Insider Ownership

CompanyInsider Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
13.20%
InterCure Ltd. stock logo
INCR
InterCure
0.24%
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
3.10%
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310218.73 million189.86 millionOptionable
InterCure Ltd. stock logo
INCR
InterCure
350N/AN/AOptionable
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
809.36 million9.07 millionN/A
Zhengye Biotechnology Holding Limited stock logo
ZYBT
Zhengye Biotechnology
27847.17 millionN/AN/A

Recent News About These Companies

Zhengye Biotechnology Holding Ltd
ZYBT Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited (ZYBT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.25 +0.01 (+0.81%)
Closing price 04:00 PM Eastern
Extended Trading
$1.26 +0.01 (+0.80%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

InterCure stock logo

InterCure NASDAQ:INCR

$1.52 +0.02 (+1.33%)
Closing price 03:57 PM Eastern
Extended Trading
$1.47 -0.05 (-3.55%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Tvardi Therapeutics stock logo

Tvardi Therapeutics NASDAQ:TVRD

$24.61 +0.63 (+2.63%)
As of 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Zhengye Biotechnology stock logo

Zhengye Biotechnology NASDAQ:ZYBT

$5.69 -0.18 (-3.07%)
As of 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.